A large pharma/IVD concern, overextended into too many areas, has handed off a business unit to an experienced niche player. Novartis has sold it's blood testing business to Spain-based Grifols, Inc. for 1.7 billion. The buyer is no stranger to the blood market. The company has a rich history dating to the development of plasmapheresis by Dr. Josep Antoni Grifols in 1951, and has continued to innovate. The company introduced NAT testing to detect hepatitis C (HCV) virus in plasma fractionation pools, two years before it became compulsory in 1997.